Temporal trends and long-term outcomes of radiofrequency ablation for hepatocellular carcinoma within the Milan criteria

被引:0
作者
Jang, Se Young [1 ]
Park, Soo Young [1 ]
Kweon, Young Oh [1 ]
Lee, Yu Rim [1 ]
Ryeom, Hun Kyu [2 ]
Cha, Jung Guen [2 ]
Kim, Sungmin [3 ]
Lee, Won Kee [4 ]
Jo, Ae Jeong [5 ]
Tak, Won Young [1 ]
机构
[1] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea
[2] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Radiol, Daegu, South Korea
[3] Univ Ulsan, Dept Biomed Engn, Ulsan, South Korea
[4] Kyungpook Natl Univ, Sch Med, Dept Med Informat, Daegu, South Korea
[5] Andong Natl Univ, Dept Informat Stat, Andong, South Korea
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
基金
新加坡国家研究基金会;
关键词
THERMOSENSITIVE LIPOSOMAL DOXORUBICIN; 1ST-LINE TREATMENT; PROGNOSTIC-FACTORS; THERAPY; ANALOGS;
D O I
10.1038/s41598-024-70494-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
No study has analysed the temporal trends of the long-term results and clinical characteristics of patients with hepatocellular carcinoma (HCC) treated using radiofrequency ablation (RFA). Therefore, we examined temporal trends of characteristics of patients and treatment-na & iuml;ve HCCs within the Milan criteria treated by RFA over 20 years. We retrospectively analysed 1099 patients with HCC within the Milan criteria treated with percutaneous RFA from January 2000 to December 2019. The overall survival (OS), recurrence-free survival (RFS), and factors affecting survival and local tumor progression were analysed using the Kaplan-Meier method and Cox proportional hazards model. A trend test was performed to analyse the changing trends in participants and treatment outcomes. The overall and RFS of patients improved during the later period. In addition, viral hepatitis-related HCC incidence decreased, whereas that of alcohol- or non-alcoholic fatty liver disease-related HCC increased from the earlier to the later period (P for trend < 0.001). HBV antiviral therapy was increased and improved OS and RFS in patients treated using RFA. The outcomes after RFA over a 20-year period improved due to changes over time in target tumors and patients. The results could be useful for selecting patients who will benefit from RFA.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] Thrombocytopenia associated with chronic liver disease
    Afdhal, Nezam
    McHutchison, John
    Brown, Robert
    Jacobson, Ira
    Manns, Michael
    Poordad, Fred
    Weksler, Babette
    Esteban, Rafael
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 (06) : 1000 - 1007
  • [2] Ahmed M, 2014, RADIOLOGY, V273, P241, DOI [10.1148/radiol.14132958, 10.1016/j.jvir.2014.08.027]
  • [3] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [4] Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series
    Choi, Dongil
    Lim, Hyo K.
    Rhim, Hyunchul
    Kim, Young-sun
    Lee, Won Jae
    Paik, Seung Woon
    Koh, Kwang Cheol
    Lee, Joon Hyoek
    Choi, Moon Seok
    Yoo, Byung Chul
    [J]. EUROPEAN RADIOLOGY, 2007, 17 (03) : 684 - 692
  • [5] Increasing Burden of Liver Cancer Despite Extensive Use of Antiviral Agents in a Hepatitis B Virus-Endemic Population
    Choi, Jonggi
    Han, Seungbong
    Kim, Namkug
    Lim, Young-Suk
    [J]. HEPATOLOGY, 2017, 66 (05) : 1454 - 1463
  • [6] Couinaud C., 1957, FOIE ETUDES ANATOMIQ
  • [7] Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma
    Cucchetti, Alessandro
    Piscaglia, Fabio
    Cescon, Matteo
    Colecchia, Antonio
    Ercolani, Giorgio
    Bolondi, Luigi
    Pinna, Antonio D.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (02) : 300 - 307
  • [8] European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
  • [9] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018)
    Galle, Peter R.
    Forner, Alejandro
    Llovet, Josep M.
    Mazzaferro, Vincenzo
    Piscaglia, Fabio
    Raoul, Jean-Luc
    Schirmacher, Peter
    Vilgrain, Valerie
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (04) : 817 - 817
  • [10] Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels A Randomized Controlled Trial
    Huang, Gang
    Li, Peng-peng
    Lau, Wan Yee
    Pan, Ze-ya
    Zhao, Ling-hao
    Wang, Zhen-guang
    Wang, Meng-chao
    Zhou, Wei-ping
    [J]. ANNALS OF SURGERY, 2018, 268 (06) : 943 - 954